U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

FIGO Stage III Ovarian Cancer

MedGen UID:
924538
•Concept ID:
C4284040
•
Neoplastic Process
Synonym: FIGO Stage III Ovarian Carcinoma

Definition

Ovarian cancer involving 1 or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes. (FIGO, 2014) [from NCI]

Professional guidelines

PubMed

The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.
Wang X, Wang S, Yao S, Shi W, Ma K
J Ovarian Res 2022 Sep 16;15(1):104. doi: 10.1186/s13048-022-01037-6. PMID: 36114551Free PMC Article
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL, Bryant A, Kehoe S, Morrison J
Cochrane Database Syst Rev 2021 Jul 30;7(7):CD005343. doi: 10.1002/14651858.CD005343.pub6. PMID: 34328210Free PMC Article
First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD, Morgan RD, Edmondson RJ, Clamp AR, Jayson GC
Curr Oncol Rep 2020 Jun 4;22(6):64. doi: 10.1007/s11912-020-00933-8. PMID: 32494876Free PMC Article

Recent clinical studies

Etiology

Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes.
Ghirardi V, Trozzi R, Scanu FR, Giannarelli D, Santullo F, Costantini B, Naldini A, Panico C, Frassanito L, Scambia G, Fagotti A
Ann Surg Oncol 2024 May;31(5):3350-3360. Epub 2024 Feb 27 doi: 10.1245/s10434-024-15042-0. PMID: 38411761Free PMC Article
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group
Int J Gynecol Cancer 2020 Jun;30(6):888-892. Epub 2020 Mar 23 doi: 10.1136/ijgc-2020-001231. PMID: 32205449Free PMC Article
Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab.
Kuk A, Magnowska M, Suchy W, Swierczynska J, Zaborowski MP, Gaca M, Nowak-Markwitz E
Target Oncol 2017 Aug;12(4):495-503. doi: 10.1007/s11523-017-0496-3. PMID: 28580507Free PMC Article
Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
Liutkauskiene S, Janciauskiene R, Jureniene K, Grizas S, Malonyte R, Juozaityte E
BMC Cancer 2015 Mar 7;15:105. doi: 10.1186/s12885-015-1104-5. PMID: 25879527Free PMC Article
Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.
Rochet N, Lindel K, Katayama S, Schubert K, Herfarth K, Schneeweiss A, Sohn C, Harms W, Debus J
Strahlenther Onkol 2015 Jul;191(7):582-9. Epub 2015 Mar 19 doi: 10.1007/s00066-015-0830-6. PMID: 25786589

Diagnosis

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group
Int J Gynecol Cancer 2020 Jun;30(6):888-892. Epub 2020 Mar 23 doi: 10.1136/ijgc-2020-001231. PMID: 32205449Free PMC Article
Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab.
Kuk A, Magnowska M, Suchy W, Swierczynska J, Zaborowski MP, Gaca M, Nowak-Markwitz E
Target Oncol 2017 Aug;12(4):495-503. doi: 10.1007/s11523-017-0496-3. PMID: 28580507Free PMC Article
Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay.
Raspollini MR, Pinzani P, Pazzagli M, Baroni G, Taddei A, Amunni G, Villanucci A, Taddei GL
J Chemother 2002 Oct;14(5):518-25. doi: 10.1179/joc.2002.14.5.518. PMID: 12462432
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M
Gynecol Oncol 2000 May;77(2):258-63. doi: 10.1006/gyno.2000.5728. PMID: 10785475
The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer.
Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB
Ann Oncol 1999 Nov;10(11):1335-41. doi: 10.1023/a:1008352502465. PMID: 10631462

Therapy

Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes.
Ghirardi V, Trozzi R, Scanu FR, Giannarelli D, Santullo F, Costantini B, Naldini A, Panico C, Frassanito L, Scambia G, Fagotti A
Ann Surg Oncol 2024 May;31(5):3350-3360. Epub 2024 Feb 27 doi: 10.1245/s10434-024-15042-0. PMID: 38411761Free PMC Article
Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN, Kieffer JM, K Sikorska, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham MAPC, Aalbers AG, Verwaal VJ, Van de Vijver KK, Sonke GS, van Driel WJ, Aaronson NK
Eur J Surg Oncol 2021 Jan;47(1):101-107. Epub 2019 May 13 doi: 10.1016/j.ejso.2019.05.006. PMID: 31128948
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group
Int J Gynecol Cancer 2020 Jun;30(6):888-892. Epub 2020 Mar 23 doi: 10.1136/ijgc-2020-001231. PMID: 32205449Free PMC Article
Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab.
Kuk A, Magnowska M, Suchy W, Swierczynska J, Zaborowski MP, Gaca M, Nowak-Markwitz E
Target Oncol 2017 Aug;12(4):495-503. doi: 10.1007/s11523-017-0496-3. PMID: 28580507Free PMC Article
Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
Liutkauskiene S, Janciauskiene R, Jureniene K, Grizas S, Malonyte R, Juozaityte E
BMC Cancer 2015 Mar 7;15:105. doi: 10.1186/s12885-015-1104-5. PMID: 25879527Free PMC Article

Prognosis

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group
Int J Gynecol Cancer 2020 Jun;30(6):888-892. Epub 2020 Mar 23 doi: 10.1136/ijgc-2020-001231. PMID: 32205449Free PMC Article
Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab.
Kuk A, Magnowska M, Suchy W, Swierczynska J, Zaborowski MP, Gaca M, Nowak-Markwitz E
Target Oncol 2017 Aug;12(4):495-503. doi: 10.1007/s11523-017-0496-3. PMID: 28580507Free PMC Article
Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
Liutkauskiene S, Janciauskiene R, Jureniene K, Grizas S, Malonyte R, Juozaityte E
BMC Cancer 2015 Mar 7;15:105. doi: 10.1186/s12885-015-1104-5. PMID: 25879527Free PMC Article
Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.
Rochet N, Lindel K, Katayama S, Schubert K, Herfarth K, Schneeweiss A, Sohn C, Harms W, Debus J
Strahlenther Onkol 2015 Jul;191(7):582-9. Epub 2015 Mar 19 doi: 10.1007/s00066-015-0830-6. PMID: 25786589
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M
Gynecol Oncol 2000 May;77(2):258-63. doi: 10.1006/gyno.2000.5728. PMID: 10785475

Clinical prediction guides

Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes.
Ghirardi V, Trozzi R, Scanu FR, Giannarelli D, Santullo F, Costantini B, Naldini A, Panico C, Frassanito L, Scambia G, Fagotti A
Ann Surg Oncol 2024 May;31(5):3350-3360. Epub 2024 Feb 27 doi: 10.1245/s10434-024-15042-0. PMID: 38411761Free PMC Article
Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN, Kieffer JM, K Sikorska, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham MAPC, Aalbers AG, Verwaal VJ, Van de Vijver KK, Sonke GS, van Driel WJ, Aaronson NK
Eur J Surg Oncol 2021 Jan;47(1):101-107. Epub 2019 May 13 doi: 10.1016/j.ejso.2019.05.006. PMID: 31128948
Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab.
Kuk A, Magnowska M, Suchy W, Swierczynska J, Zaborowski MP, Gaca M, Nowak-Markwitz E
Target Oncol 2017 Aug;12(4):495-503. doi: 10.1007/s11523-017-0496-3. PMID: 28580507Free PMC Article
Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay.
Raspollini MR, Pinzani P, Pazzagli M, Baroni G, Taddei A, Amunni G, Villanucci A, Taddei GL
J Chemother 2002 Oct;14(5):518-25. doi: 10.1179/joc.2002.14.5.518. PMID: 12462432
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M
Gynecol Oncol 2000 May;77(2):258-63. doi: 10.1006/gyno.2000.5728. PMID: 10785475

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...